Comparison of the characteristics at diagnosis and treatment of
children with heterozygous familial hypercholesterolaemia (FH)
from eight European countries

J 2020

Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries

RAMASWAMI, U., M. FUTEMA, M. P. BOGSRUD, K. B. HOLVEN, J. R. VAN LENNEP et. al.

Základní údaje

Originální název

Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries

Autoři

RAMASWAMI, U. (826 Velká Británie a Severní Irsko), M. FUTEMA (826 Velká Británie a Severní Irsko), M. P. BOGSRUD (578 Norsko), K. B. HOLVEN (578 Norsko), J. R. VAN LENNEP (528 Nizozemské království), A. WIEGMAN (528 Nizozemské království), O. S. DESCAMPS (56 Belgie), M. VRABLIK (203 Česká republika), Tomáš FREIBERGER (203 Česká republika, domácí), H. DIEPLINGER (40 Rakousko), S. GREBER-PLATZER (40 Rakousko), G. HANAUER-MADER (40 Rakousko), M. BOURBON (620 Portugalsko), E. DROGARI (300 Řecko) a S. E. HUMPHRIES (826 Velká Británie a Severní Irsko, garant)

Vydání

Atherosclerosis, Clare, ELSEVIER SCI IRELAND LTD, 2020, 0021-9150

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.162

Kód RIV

RIV/00216224:14110/20:00115978

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.atherosclerosis.2019.11.012

UT WoS

000503400300024

Klíčová slova anglicky

Heterozygous familial hypercholesterolaemia; Paediatric FH; LDL-C concentrations; Statin treatment

Štítky

14110114, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 15. 7. 2020 08:10, Mgr. Tereza Miškechová

Anotace

V originále

Background and aims: For children with heterozygous familial hypercholesterolaemia (HeFH), European guidelines recommend consideration of statin therapy by age 8-10 years for those with a low density lipoprotein cholesterol (LDL-C) > 3.5 mmol/l, and dietary and lifestyle advice. Here we compare the characteristics and lipid levels in HeFH children from Norway, UK, Netherlands, Belgium, Czech Republic, Austria, Portugal and Greece. Methods: Fully-anonymized data were analysed at the London centre. Differences in registration and on treatment characteristics were compared by standard statistical tests. Results: Data was obtained from 3064 children. The median age at diagnosis differed significantly between countries (range 3-11 years) reflecting differences in diagnostic strategies. Mean (SD) LDL-C at diagnosis was 5.70 (+/- 1.4) mmol/l, with 88% having LDL-C > 4.0 mmol/l. The proportion of children older than 10 years at follow-up who were receiving statins varied significantly (99% in Greece, 56% in UK), as did the proportion taking Ezetimibe (0% in UK, 78% in Greece). Overall, treatment reduced LDL-C by between 28 and 57%, however, in those > 10 years, 23% of on-treatment children still had LDL-C > 3.5 mmol/l and 66% of those not on a statin had LDL-C > 3.5 mmol/l. Conclusions: The age of HeFH diagnosis in children varies significantly across 8 countries, as does the proportion of those > 10 years being treated with statin and/or ezetimibe. Approximately a quarter of the treated children and almost three quarters of the untreated children older than 10 years still have LDL-C concentrations over 3.5 mmol/l. These data suggest that many children with FH are not receiving the full potential benefit of early identification and appropriate lipid-lowering treatment according to recommendations.

Citovat

RAMASWAMI, U., M. FUTEMA, M. P. BOGSRUD, K. B. HOLVEN, J. R. VAN LENNEP, A. WIEGMAN, O. S. DESCAMPS, M. VRABLIK, Tomáš FREIBERGER, H. DIEPLINGER, S. GREBER-PLATZER, G. HANAUER-MADER, M. BOURBON, E. DROGARI a S. E. HUMPHRIES. Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. Atherosclerosis. Clare: ELSEVIER SCI IRELAND LTD, 2020, roč. 292, JAN 2020, s. 178-187. ISSN 0021-9150. Dostupné z: https://dx.doi.org/10.1016/j.atherosclerosis.2019.11.012.

@article{1670343,
   author = {Ramaswami, U. and Futema, M. and Bogsrud, M. P. and Holven, K. B. and van Lennep, J. R. and Wiegman, A. and Descamps, O. S. and Vrablik, M. and Freiberger, Tomáš and Dieplinger, H. and GreberandPlatzer, S. and HanauerandMader, G. and Bourbon, M. and Drogari, E. and Humphries, S. E.},
   article_location = {Clare},
   article_number = {JAN 2020},
   doi = {http://dx.doi.org/10.1016/j.atherosclerosis.2019.11.012},
   keywords = {Heterozygous familial hypercholesterolaemia; Paediatric FH; LDL-C concentrations; Statin treatment},
   language = {eng},
   issn = {0021-9150},
   journal = {Atherosclerosis},
   title = {Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries},
   url = {https://www.atherosclerosis-journal.com/article/S0021-9150(19)31569-2/pdf},
   volume = {292},
   year = {2020}
}

TY  - JOUR
ID  - 1670343
AU  - Ramaswami, U. - Futema, M. - Bogsrud, M. P. - Holven, K. B. - van Lennep, J. R. - Wiegman, A. - Descamps, O. S. - Vrablik, M. - Freiberger, Tomáš - Dieplinger, H. - Greber-Platzer, S. - Hanauer-Mader, G. - Bourbon, M. - Drogari, E. - Humphries, S. E.
PY  - 2020
TI  - Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries
JF  - Atherosclerosis
VL  - 292
IS  - JAN 2020
SP  - 178-187
EP  - 178-187
PB  - ELSEVIER SCI IRELAND LTD
SN  - 00219150
KW  - Heterozygous familial hypercholesterolaemia
KW  - Paediatric FH
KW  - LDL-C concentrations
KW  - Statin treatment
UR  - https://www.atherosclerosis-journal.com/article/S0021-9150(19)31569-2/pdf
L2  - https://www.atherosclerosis-journal.com/article/S0021-9150(19)31569-2/pdf
N2  - Background and aims: For children with heterozygous familial hypercholesterolaemia (HeFH), European guidelines recommend consideration of statin therapy by age 8-10 years for those with a low density lipoprotein cholesterol (LDL-C) > 3.5 mmol/l, and dietary and lifestyle advice. Here we compare the characteristics and lipid levels in HeFH children from Norway, UK, Netherlands, Belgium, Czech Republic, Austria, Portugal and Greece. Methods: Fully-anonymized data were analysed at the London centre. Differences in registration and on treatment characteristics were compared by standard statistical tests. Results: Data was obtained from 3064 children. The median age at diagnosis differed significantly between countries (range 3-11 years) reflecting differences in diagnostic strategies. Mean (SD) LDL-C at diagnosis was 5.70 (+/- 1.4) mmol/l, with 88% having LDL-C > 4.0 mmol/l. The proportion of children older than 10 years at follow-up who were receiving statins varied significantly (99% in Greece, 56% in UK), as did the proportion taking Ezetimibe (0% in UK, 78% in Greece). Overall, treatment reduced LDL-C by between 28 and 57%, however, in those > 10 years, 23% of on-treatment children still had LDL-C > 3.5 mmol/l and 66% of those not on a statin had LDL-C > 3.5 mmol/l. Conclusions: The age of HeFH diagnosis in children varies significantly across 8 countries, as does the proportion of those > 10 years being treated with statin and/or ezetimibe. Approximately a quarter of the treated children and almost three quarters of the untreated children older than 10 years still have LDL-C concentrations over 3.5 mmol/l. These data suggest that many children with FH are not receiving the full potential benefit of early identification and appropriate lipid-lowering treatment according to recommendations.
ER  -

RAMASWAMI, U., M. FUTEMA, M. P. BOGSRUD, K. B. HOLVEN, J. R. VAN LENNEP, A. WIEGMAN, O. S. DESCAMPS, M. VRABLIK, Tomáš FREIBERGER, H. DIEPLINGER, S. GREBER-PLATZER, G. HANAUER-MADER, M. BOURBON, E. DROGARI a S. E. HUMPHRIES. Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. \textit{Atherosclerosis}. Clare: ELSEVIER SCI IRELAND LTD, 2020, roč.~292, JAN 2020, s.~178-187. ISSN~0021-9150. Dostupné z: https://dx.doi.org/10.1016/j.atherosclerosis.2019.11.012.

Podrobný výpis o publikaci